Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGLT2 Inhibitors in Hemodialysis Patients
NCT06929169Phase 2Recruiting
- Start
- May 2025
- Primary completion
- Jul 2026
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in end-stage kidney disease (ESKD) (2 arms). Primary endpoints: Change in Left Ventricular Mass Index at Month 12, Change in Left Ventricular Ejection Fraction at Month 12 and 3 more. Started May 2025; status: recruiting.
02
Conditions
end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on NCT06929169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06929169.